GLP-1 drugs show no overall cancer risk increase but raise thyroid cancer signal in meta-analysis of 50 trials
Meta-analysis of 50 RCTs found GLP-1 drugs do not increase overall cancer risk (OR 1.05, NS), but detected a significant thyroid cancer signal (OR 1.55) and colorectal cancer increase (OR 1.27), while uterine cancer was reduced in obesity trials (OR 0.24).
Quick Facts
What This Study Found
Overall cancer: MH-OR 1.05 (NS). Thyroid cancer: OR 1.55 (1.05-2.27, significant, worse in longer trials). Colorectal cancer: OR 1.27 (1.03-1.57, significant in shorter trials only). Uterine cancer in obesity: OR 0.24 (0.06-0.94, significant). No other cancers affected.
Key Numbers
How They Did This
Meta-analysis of 50 RCTs comparing GLP-1RAs to any comparators for diabetes/obesity, lasting ≥52 weeks. Endpoints: overall and site-specific cancer incidence.
Why This Research Matters
With millions taking GLP-1 drugs, cancer safety is critical. This analysis reassures about overall cancer risk but identifies thyroid cancer as a genuine concern requiring ongoing monitoring and uterine cancer reduction as an important benefit.
The Bigger Picture
The thyroid cancer signal with GLP-1 drugs has been a long-standing concern since animal studies showed thyroid C-cell hyperplasia. This meta-analysis provides the most robust human evidence yet that the risk may be real, though the absolute increase is small.
What This Study Doesn't Tell Us
Cancer as a secondary outcome in most trials (not powered for cancer detection). Short follow-up for cancer development. Thyroid cancer screening practices may vary. Colorectal increase may reflect diagnostic bias.
Questions This Raises
- ?Should thyroid screening be recommended for long-term GLP-1 drug users?
- ?Does the uterine cancer reduction persist with longer follow-up?
- ?Is the colorectal cancer signal real or an artifact of increased diagnostic workup?
Trust & Context
- Key Stat:
- Thyroid cancer OR 1.55 GLP-1 drugs showed a significant 55% increase in thyroid cancer risk in meta-analysis of 50 trials, more evident with longer use
- Evidence Grade:
- Large meta-analysis of 50 RCTs. Strong for overall cancer reassurance. Thyroid signal is significant but based on small event numbers. Needs prospective cancer-focused studies.
- Study Age:
- Published in 2025.
- Original Title:
- GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials.
- Published In:
- Diabetes, obesity & metabolism, 27(8), 4454-4468 (2025)
- Authors:
- Silverii, Giovanni Antonio(3), Marinelli, Christian, Bettarini, Costanza, Del Vescovo, Gloria Giovanna, Monami, Matteo, Mannucci, Edoardo
- Database ID:
- RPEP-13606
Evidence Hierarchy
Frequently Asked Questions
Do GLP-1 drugs cause cancer?
This analysis of 50 clinical trials found no increase in overall cancer risk. However, thyroid cancer risk was 55% higher with GLP-1 drugs, especially with longer use. Colorectal cancer showed a small increase that may be due to more diagnostic testing rather than actual cancer. Importantly, uterine cancer risk was 76% lower in obese patients.
Should I be worried about thyroid cancer on semaglutide?
The absolute risk increase is small, and thyroid cancer is generally very treatable. However, the signal is statistically significant and more pronounced with longer-term use. If you have thyroid cancer risk factors or notice neck lumps, discuss monitoring with your doctor. The overall benefits of GLP-1 drugs (mortality reduction, cardiovascular protection) far outweigh this risk for most patients.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13606APA
Silverii, Giovanni Antonio; Marinelli, Christian; Bettarini, Costanza; Del Vescovo, Gloria Giovanna; Monami, Matteo; Mannucci, Edoardo. (2025). GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials.. Diabetes, obesity & metabolism, 27(8), 4454-4468. https://doi.org/10.1111/dom.16489
MLA
Silverii, Giovanni Antonio, et al. "GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials.." Diabetes, 2025. https://doi.org/10.1111/dom.16489
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 receptor agonists and the risk for cancer: A meta-anal..." RPEP-13606. Retrieved from https://rethinkpeptides.com/research/silverii-2025-glp1-receptor-agonists-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.